ArkeaBio Raises $15M Series A2 to Push Its Cattle Methane Vaccine Toward Market

The Deal

ArkeaBio, the Boston-based startup building a vaccine to cut methane emissions from livestock, has closed a $15 million Series A2 round led by AgriZeroNZ with support from Breakthrough Energy.

The round follows the company's Series A1, which was co-led by AgriZeroNZ and Breakthrough Energy Ventures — making this the latest step in a steadily deepening relationship between ArkeaBio and both investors.

CEO Frank Wooten said the new money is likely to carry ArkeaBio through to its first commercial product, a notable claim for a company working in a category where most entrants are still years from the market.

How the Vaccine Works

The approach is deceptively simple in outline: the vaccine prompts a cow's immune system to produce antibodies that interfere with methanogens — the microbes in the rumen responsible for generating methane during digestion.

Suppressing those methanogens changes the chemistry of the rumen. Hydrogen that would otherwise be consumed in making methane is instead available to other microbes, which use it to produce compounds such as volatile fatty acids.

• Those compounds could help cows produce more milk and meat, offering a potential productivity upside alongside the emissions cut.
• That dual benefit matters commercially: it gives farmers a reason to adopt the product beyond climate compliance alone.

AgriZeroNZ credits ArkeaBio as the first company to have demonstrated methane reduction in cattle from a vaccine, based on trials conducted with researchers at Texas A&M University.

Technical Targets: Second-Generation Formulation

ArkeaBio has moved on to a second-generation vaccine formulation, and the targets it has set out give a sense of what a viable commercial product would need to look like.

• Durability: a vaccine that remains effective for six months or more per dose.
• Efficacy: roughly a 20% reduction in methane emissions.

The durability goal is arguably as important as the efficacy figure. A vaccine that needs frequent re-dosing would erode the central advantage of the approach — that it slots into handling routines farmers already follow.

Narrowing Focus and Cutting Headcount

Alongside the raise, ArkeaBio has reduced its headcount by about a third, releasing both scientists and commercial staff in order to extend its runway.

Wooten frames the cuts not as a retreat but as a consequence of moving closer to commercialization: the company is concentrating on its initial market, its initial product and its initial revenues rather than funding a broad research program.

That initial market is New Zealand — a country whose emissions profile is unusually dominated by agriculture, and whose policy environment has produced one of ArkeaBio's largest backers.

Why a Vaccine, and Not a Feed Additive

Wooten, a cofounder of virtual fencing company Vence, joined ArkeaBio as CEO in September 2025. His case for the vaccine route rests less on biology than on logistics.

• Vaccines are already used in 100% of livestock markets worldwide, so the delivery infrastructure — cold chain, veterinary practice, farmer familiarity — is effectively a solved problem.
• Most animals outside the US are never put on feed, which sharply limits how many cattle a feed-based intervention can actually reach.

On that reading, a vaccine is the most cost-effective option at scale. It is not the only one being pursued, though: other approaches to livestock methane include cattle breeding programs, feed additives and gene editing of rumen microbes.

AgriZeroNZ's Escalating Bet

AgriZeroNZ, the New Zealand joint venture backing agricultural emissions technology, has steadily increased its exposure to ArkeaBio.

• An initial investment of USD $6 million in 2024.
• A further USD $3.5 million (approximately NZD $5.9 million) in September 2025.
• Now, leadership of the $15 million Series A2.

The venture has described the vaccine as a “holy grail” approach to livestock methane — language that reflects both the scale of the prize and how long the sector has been chasing it.

What Remains Unclear

For all the specificity of ArkeaBio's technical targets, the commercial timeline remains thin. Available disclosures do not specify a regulatory filing date for the vaccine, and no commercial launch date has been publicly confirmed.

Two questions stand out from here:

• Whether the roughly 20% methane reduction target holds up in field conditions, across varied herds and diets, rather than in trial settings.
• What the path to regulatory approval in New Zealand actually looks like, given that it is the company's first intended market.

Until those are answered, the Series A2 buys ArkeaBio something more modest than certainty: enough runway, by its CEO's account, to find out whether a first commercial product is reachable.